BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19 high B lymphocytes
ConclusionsBTLA detected in cancerous tissues can predict poor outcome of EOC patients. Inhibition of BTLA combined with chemotherapy can elevate immune activation and generate potent anti-tumor effects. Thus, the combination of chemotherapy and anti-BTLA antibody may hold potential clinical application for the treatment of EOC patients.Trial registrationThe Trial Registration Number wasNCT00854399.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Chemotherapy | Epithelial Cancer | Immunotherapy | Ovarian Cancer | Ovaries | Study